Zentalis Pharma Files 8-K for Financial Results
Ticker: ZNTL · Form: 8-K · Filed: Feb 27, 2024 · CIK: 1725160
Sentiment: neutral
Topics: financial-results, 8-K, corporate-filing
Related Tickers: ZNTL
TL;DR
**Zentalis Pharmaceuticals just filed an 8-K announcing its financial results, get ready for the numbers!**
AI Summary
Zentalis Pharmaceuticals, Inc. filed an 8-K on February 27, 2024, to report its Results of Operations and Financial Condition, including Financial Statements and Exhibits. This filing, identified by accession number 0001725160-24-000079, signals the company's disclosure of its latest financial performance, though specific figures are not detailed in this excerpt. The company's CIK is 0001725160, and its business address is 1359 Broadway, Suite 801, New York, NY 10018.
Why It Matters
This 8-K indicates Zentalis Pharmaceuticals is disclosing its latest financial performance, which is crucial for investors to assess the company's health and future prospects. The actual financial data, once available, will inform investment decisions and market sentiment.
Risk Assessment
Risk Level: medium — The filing concerns financial results, which can significantly impact stock price depending on whether the results are positive or negative, introducing market volatility.
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — filer
- 03 Life Sciences (company) — organization name
- February 27, 2024 (date) — date of report
FAQ
What company filed this 8-K?
Zentalis Pharmaceuticals, Inc. filed this 8-K.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is February 27, 2024.
What specific items are reported in this 8-K?
The 8-K reports on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
What is the Central Index Key (CIK) for Zentalis Pharmaceuticals, Inc.?
The CIK for Zentalis Pharmaceuticals, Inc. is 0001725160.
What is the business address of Zentalis Pharmaceuticals, Inc.?
The business address is 1359 Broadway, Suite 801, New York, NY 10018.
Filing Stats: 568 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-02-27 07:04:11
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ZNTL The Nasdaq Glo
Filing Documents
- zntl-20240227.htm (8-K) — 33KB
- zntl_q42023earningspr.htm (EX-99.1) — 71KB
- zenalis_primarybluenavya.jpg (GRAPHIC) — 67KB
- 0001725160-24-000079.txt ( ) — 355KB
- zntl-20240227.xsd (EX-101.SCH) — 2KB
- zntl-20240227_def.xml (EX-101.DEF) — 5KB
- zntl-20240227_lab.xml (EX-101.LAB) — 30KB
- zntl-20240227_pre.xml (EX-101.PRE) — 18KB
- zntl-20240227_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 27, 2024, Zentalis Pharmaceuticals, Inc. (the "Company") announced its financial results for the year ended December 31, 2023 and commented on certain business updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated herein by reference. The information in Item 2.02 of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release issued on February 27, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: February 27, 2024 By: /s/ Melissa Epperly Melissa Epperly Chief Financial Officer